PURPOSE: Radioimmunotherapy (RIT) using (131)I-3F8 injected into cerebrospinal fluid (CSF) was a safe modality for the treatment of leptomeningeal metastases (JCO, 25:5465, 2007). A single-compartment pharmacokinetic model described previously (JNM 50:1324, 2009) showed good fitting to the CSF radioactivity data obtained from patients. We now describe a two-compartment model to account for the ventricular reservoir of (131)I-3F8 and to identify limiting factors that may impact therapeutic ratio. METHODS: Each parameter was examined for its effects on (1) the area under the radioactivity concentration curve of the bound antibody (AUC[C(IAR)]), (2) that of the unbound antibody AUC[C(IA)], and (3) their therapeutic ratio (AUC[C(IAR)]/AUC[C(IA)]). RESULTS: Data fitting showed that CSF kBq/ml data fitted well using the two-compartment model (R = 0.95 ± 0.03). Correlations were substantially better when compared to the one-compartment model (R = 0.92 ± 0.11 versus 0.77 ± 0.21, p = 0.005). In addition, we made the following new predictions: (1) Increasing immunoreactivity of (131)I-3F8 from 10% to 90% increased both (AUC[C(IAR)]) and therapeutic ratio ([AUC[C(IAR)]/AUC[C(IA)]] by 7.4 fold, (2) When extrapolated to the clinical setting, the model predicted that if (131)I-3F8 could be split into 4 doses of 1.4 mg each and given at ≥24 hours apart, an antibody affinity of K(D) of 4 × 10(-9) at 50% immunoreactivity were adequate in order to deliver ≥100 Gy to tumor cells while keeping normal CSF exposure to <10 Gy. CONCLUSIONS: This model predicted that immunoreactivity, affinity and optimal scheduling of antibody injections were crucial in improving therapeutic index.
PURPOSE: Radioimmunotherapy (RIT) using (131)I-3F8 injected into cerebrospinal fluid (CSF) was a safe modality for the treatment of leptomeningeal metastases (JCO, 25:5465, 2007). A single-compartment pharmacokinetic model described previously (JNM 50:1324, 2009) showed good fitting to the CSF radioactivity data obtained from patients. We now describe a two-compartment model to account for the ventricular reservoir of (131)I-3F8 and to identify limiting factors that may impact therapeutic ratio. METHODS: Each parameter was examined for its effects on (1) the area under the radioactivity concentration curve of the bound antibody (AUC[C(IAR)]), (2) that of the unbound antibody AUC[C(IA)], and (3) their therapeutic ratio (AUC[C(IAR)]/AUC[C(IA)]). RESULTS: Data fitting showed that CSF kBq/ml data fitted well using the two-compartment model (R = 0.95 ± 0.03). Correlations were substantially better when compared to the one-compartment model (R = 0.92 ± 0.11 versus 0.77 ± 0.21, p = 0.005). In addition, we made the following new predictions: (1) Increasing immunoreactivity of (131)I-3F8 from 10% to 90% increased both (AUC[C(IAR)]) and therapeutic ratio ([AUC[C(IAR)]/AUC[C(IA)]] by 7.4 fold, (2) When extrapolated to the clinical setting, the model predicted that if (131)I-3F8 could be split into 4 doses of 1.4 mg each and given at ≥24 hours apart, an antibody affinity of K(D) of 4 × 10(-9) at 50% immunoreactivity were adequate in order to deliver ≥100 Gy to tumor cells while keeping normal CSF exposure to <10 Gy. CONCLUSIONS: This model predicted that immunoreactivity, affinity and optimal scheduling of antibody injections were crucial in improving therapeutic index.
Authors: H M Thierens; M A Monsieurs; B Brans; T Van Driessche ; I Christiaens; R A Dierckx Journal: Comput Med Imaging Graph Date: 2001 Mar-Apr Impact factor: 4.790
Authors: G D Silverberg; G Heit; S Huhn; R A Jaffe; S D Chang; H Bronte-Stewart; E Rubenstein; K Possin; T A Saul Journal: Neurology Date: 2001-11-27 Impact factor: 9.910
Authors: R R Eger; D G Covell; J A Carrasquillo; P G Abrams; K A Foon; J C Reynolds; R W Schroff; A C Morgan; S M Larson; J N Weinstein Journal: Cancer Res Date: 1987-06-15 Impact factor: 12.701
Authors: Mahiuddin Ahmed; Ming Cheng; Qi Zhao; Yehuda Goldgur; Sarah M Cheal; Hong-fen Guo; Steven M Larson; Nai-kong V Cheung Journal: J Biol Chem Date: 2015-10-20 Impact factor: 5.157
Authors: Eugene I Hwang; Elias J Sayour; Catherine T Flores; Gerald Grant; Robert Wechsler-Reya; Lan B Hoang-Minh; Mark W Kieran; Joanne Salcido; Robert M Prins; John W Figg; Michael Platten; Kate M Candelario; Paul G Hale; Jason E Blatt; Lance S Governale; Hideho Okada; Duane A Mitchell; Ian F Pollack Journal: Nat Cancer Date: 2022-01-20
Authors: Rahul S Yerrabelli; Ping He; Edward K Fung; Kim Kramer; Pat B Zanzonico; John L Humm; Hongfen Guo; Neeta Pandit-Taskar; Steven M Larson; Nai-Kong V Cheung Journal: Eur J Nucl Med Mol Imaging Date: 2020-10-13 Impact factor: 9.236